Spinal Muscular Atrophy market

View All

Spinal Muscular Atrophy Therapies
How Spinal Muscular Atrophy Therapies transform market?

Spinal Muscular Atrophy is a rare and the second most fatal autosomal recessive genetic disorder with an incidence of 1 in 6000 to 1 in 10,000 births. Globally talking, SMA prevalence was reported in 19,343 cases in the year 2017 in the 7MM, and the US accounted for the highest number of cases approximately around ...

Find More

Gene Therapy
The era of Gene therapy, and the Billion Dollar tag

The era, we are living in has experienced many advancements in the healthcare system. Curative, and life-changing gene therapies have started to promise a future free of prolonged illness, possessing an ability to treat, cure or ease the life-draining diseases. In a major event, the approval of the other gene t...

Find More

Meet the World’s most expensive drug: Zolgensma

The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA).  SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN pro...

Find More

Spinal Muscular Atrophy
Spinal Muscular Atrophy Market

SMA (Spinal Muscular Atrophy) - a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or breathing. Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028). ...

Find More

Spinal Muscular Atrophy Therapies
Spinal Muscular Atrophy: Current and Emerging Therapies

Spinal muscular atrophy (SMA) being a rare genetic neuromuscular disorder results in progressive muscle weakness and atrophy. It affects the part of the nervous system that controls voluntary muscle movement. Spinal Muscular Atrophy Current therapeutic management revolves around supportive and multidisciplinary car...

Find More

Spinal Muscular Atrophy
Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42%

Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons in the Spinal Cord. SMA is one of the most common causes of infant mortality and mobility impairment. Spinal Muscular A...

Find More

Spinal Muscular Atrophy
Can Spinal Muscular Atrophy be treated by Protease Inhibitors?

Spinal muscular atrophy is a genetic disorder characterised by weakness and wasting (atrophy) of skeletal muscles, used for movement. Loss of specialised nerve cells, called motor neurons which controls muscle movement, results in weakness of muscles. It mostly affects proximal muscles and respiratory muscles. SMA ...

Find More

Spinal Muscular Atrophy Emerging therapies

Spinal Muscular Atrophy (SMA) is a rare genetic and neuromuscular condition which affects mainly children. It has several distinct types such as type 1 (Werdnig-Hoffmann disease), type 2 (Dubowitz disease), type 3 (Kugelberg-Welander disease) and type 4 (Adult onset). SMN1 (Survival Motor Neuron 1) is the primary ge...

Find More